ClinicalTrials.gg
CompletedNCT03955575BAM-LIRAUpdated Jun 3, 2022

Treatment of Bile Acid Malabsorption With Liraglutide

A Phase 4 interventional study of Liraglutide 6 MG/ML and Colesevelam in Bile Acid Malabsorption, sponsored by Filip Krag Knop. Completed at 1 site in Denmark. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-03.

Sponsored by Filip Krag Knop · Phase 4, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Comparing the effect of Liraglutide on bile acid malabsorption, with colesevelam

Read the detailed description

The overall objective of the present study is to provide proof of concept that treatment with the GLP-1 receptor agonist liraglutide is efficacious (as assessed by symptom relief, i.e. response to treatment) and safe (as assessed by adverse effects) in the management of BAM and that it improves bile acid reabsorption (as assessed by SeHCAT) in these patients.

02

Conditions studied

  • Bile Acid Malabsorption
03

In context

Lead sponsor

Filip Krag Knop is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Caucasian ethnicity

      • SeHCAT-verified moderate (5-10% bile acid retention after 7 days) or severe BAM (\<5% retention)
      • Normal (for men 8.3-10.5 mmol/L; for women 7.3-9.5 mmol/L)
      • Age above 18 years and below 75 years
      • Informed and written consent
      • >18,5 kg/m2 and \<40 kg/m2
      • (HbA1c) \<48 mmol/mol

Exclusion criteria

Exclusion Criteria:

    • History of or present hepatobiliary disorder (except for non-alcoholic steatotic liver disease) and/or (ALAT) and/or serum aspartate aminotransferase (ASAT) >3 times ) or history of hepatobiliary disorder

      • Gastrointestinal disease (except for BAM), previous intestinal resection or any major intra-abdomial surgery
      • Diabetes mellitus
      • Nephropathy with \< 60 mL/min/1.73m2
      • Treatment with medicine that cannot be paused for 12 hours
      • Hypothyroidism or hyperthyroidism, if not well regulated.
      • Treatment with oral anticoagulants
      • Active or recent malignant disease
      • Any treatment or condition requiring acute or sub-acute medical or surgical intervention
      • Females of who is pregnant (tested before entering the study), breastfeeding or intend to become pregnant or is not using adequate methods, which includes Intrauterine Device (IUD), birth control pills, sexual abstinence or living in a relationship with a sterile partner.
      • Known or suspected to trial products or related products
      • Any condition considered incompatible with participation by the investigators
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Active comparator
    Liraglutide/placebo-colesevelam

    Liraglutide as active and colesevelam as placebo

    Drug: Liraglutide 6 MG/ML

  • Active comparator
    Placebo-Liraglutide/colesevelam

    Liraglutide as placebo and colesevelam as placebo

    Drug: Colesevelam

Interventions

06

What researchers measure

Primary outcomes

  1. Change in stool fequency

    Contestants will use a questionaire, which will be filled out three times during the 7 weeks periode

    Time frame: 7 weeks

Secondary outcomes

  1. Total symptoms score, quality of life scores, and biomarker.

    Total symptoms score, quality of life scores, and biomarker values will be analysed using a constrained linear mixed model with inherent baseline adjustment and with an unstructured covariance pattern. Changes since baseline within and between groups will be reported with 95% confidence intervals.

    Time frame: 7 weeks

  2. Change in SeHCAT

    Three SeHCAT scans will be made, and the difference will be evaluated

    Time frame: 7 weeks

  3. Proportions of patients tolerating the treatment and proportion of patients experiencing remission of BAM related diarrhoea

    Proportions of patients tolerating the treatment and proportion of patients experiencing remission of BAM related diarrhoea within each group will be reported with exact binomial confidence intervals and compared between groups using risk differences and Fisher's exact test.

    Time frame: 7 weeks

07

Study locations

1 site
  • Gentofte Hospital
    Hellerup, Regionh 2900, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Mar 2021, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2019
First posted
May 20, 2019
StartActual
Mar 7, 2019
Primary completionActual
Mar 10, 2021
CompletionActual
May 31, 2022
Last update
Jun 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03955575
Lead sponsor
Filip Krag Knop
Collaborators
Herlev and Gentofte Hospital
Responsible party
Filip Krag Knop (Professor, Consultant Endocrinologist, MD PhD, University Hospital, Gentofte, Copenhagen) — Sponsor-investigator
First posted
May 20, 2019
Start date
Mar 7, 2019
Primary completion
Mar 10, 2021
Completion
May 31, 2022
Last update
Jun 3, 2022

Study contacts

Filip K Knop, MD PhD
principal investigator · filip.krag.knop.01@regionh.dk

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Liraglutide · Colesevelam

Start the discussion